Tao Zhang
Zhetan Ren
Bowen Tang
Ru Man1
Yongduo Yu- 1Liaoning University of Traditional Chinese Medicine, Shenyang, China
- 2Department of General Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- 3Second Affiliated Hospital, Liaoning University of Traditional Chinese Medicine, Shenyang, China
Gastrointestinal tumors (GITs), particularly gastric and colorectal cancers, are the leading causes of cancer-related deaths worldwide. Despite advances in screening technologies and the continuous development of treatments, which have improved early diagnosis and therapeutic interventions, the morbidity and mortality rates remain high, presenting a significant challenge to global public health. While existing treatments can extend patient survival to some degree, they are often accompanied by substantial side effects. In recent years, immunotherapy has yielded positive outcomes for some patients. However, the emergence of immune escape mechanisms has hindered treatment effectiveness. As a result, there is an urgent need for new therapeutic strategies that can address the limitations of current approaches. mitophagy, a key cellular process, has gained significant attention in cancer research. It plays an essential role in maintaining cellular energy balance and metabolic stability, and is intricately linked to crucial biological processes such as drug resistance, metastasis, invasion, and the tumor microenvironment. This article aims to provide a comprehensive review of the mechanisms underlying mitophagy, examining its role in gastrointestinal cancers, particularly in relation to cellular metabolism, apoptosis, drug resistance, metastasis, invasion, and the tumor microenvironment. Additionally, it will explore the potential of mitophagy as a therapeutic target and address current clinical challenges. It is hoped that this research will offer new insights and directions for the treatment of GITs.
1 Introduction
Gastrointestinal tumors (GITs) refer to malignant tumors that occur in the gastrointestinal organs of the digestive system. According to the World Health Organization, GITs are among the most common malignancies globally, with over one million new diagnoses each year (1, 2). In 2021, approximately one million new cases of gastric cancer were reported worldwide, with nearly 780,000 deaths; the incidence of colorectal cancer continues to rise globally, particularly in economically developed regions (3, 4). Despite continuous advancements in medical technology, the incidence and mortality rates of GITs remain alarmingly high (5–7). Although GITs have been extensively studied, current treatment options still have significant limitations. Presently, the treatment of GITs relies mainly on surgery, chemotherapy, radiotherapy, and targeted therapy (8). While these treatments have extended patient survival to some extent, they are often accompanied by considerable side effects (9).
In recent years, immunotherapy has emerged as a promising new treatment strategy, showing potential in certain tumor subtypes, particularly those with high microsatellite instability (MSI-H) and deficient mismatch repair (dMMR), where it has demonstrated good clinical efficacy (10–12). However, the inconsistent effectiveness of immunotherapy, especially due to immune escape phenomena, has limited its clinical success (13).
In this context, mitochondrial autophagy, also known as mitophagy, has drawn increasing attention as a key mechanism regulating cellular immune responses. By selectively degrading damaged mitochondria, mitophagy plays a crucial role in cell survival, proliferation, and immune response (14). In particular, in tumor cells, mitophagy plays a significant role in cell growth, drug resistance, and immune evasion (15, 16). Aberrant regulation of mitophagy is closely associated with the initiation and progression of GITs, making it a hot topic in the research of novel immunotherapeutic strategies (17, 18). The enormous potential of mitophagy in tumor cells offers new hope for advancing immunotherapy.
Although some studies have explored the role of mitophagy in cancer, particularly in areas such as metabolism, drug resistance, and cell death, a comprehensive review of mitophagy mechanisms in GITs remains lacking (19, 20). Moreover, how mitophagy contributes to immune evasion, modulates the tumor microenvironment, and its potential application in immunotherapy remains underexplored. Therefore, this paper aims to systematically summarize the role of mitophagy in GITs, focusing on its involvement in tumor cell generation, progression, apoptosis, and drug resistance, while exploring its potential as a novel target for immunotherapy.
2 Current research status of GITs
GITs are a severe form of malignant tumors. Despite advancements in early screening techniques and treatment options in recent years, the high incidence and mortality rates of GITs still make them a significant challenge in global cancer prevention and control efforts. Currently, the main therapeutic strategies for GITs each have their own advantages and limitations. While surgical resection offers curative potential in early-stage GIT patients, its efficacy is limited for advanced or metastatic cases. Chemotherapy and radiotherapy can alleviate symptoms and extend survival to some extent, but they are accompanied by significant side effects and issues with drug resistance (21–23). This is particularly concerning as patients’ quality of life is often negatively impacted during the course of treatment (24, 25).
Targeted therapies, as a relatively new treatment approach, can act on specific molecular targets. However, the development of resistance and inter-patient variability hinder the widespread applicability of these treatments. Immunotherapy has shown promising clinical efficacy in certain GIT cancer subtypes, such as MSI-H and dMMR patients, yet immune escape mechanisms limit its broader application.
It is noteworthy that mitophagy regulation, as a potential adjunctive therapeutic strategy, is still in the research phase. However, it holds promise in overcoming tumor cell resistance to conventional treatments and modulating immune functions, which could lead to novel therapeutic breakthroughs. Table 1 summarizes the common therapeutic approaches for GITs, their mechanisms of action, and the associated clinical limitations.
Table 1. Common therapeutic approaches for gastrointestinal tumors.
3 The basic concept and mechanism of mitophagy
Autophagy is a fundamental catabolic process through which cells eliminate damaged organelles and misfolded proteins via the lysosomal degradation pathway. Mitophagy represents a selective subtype of autophagy that specifically targets mitochondria. As the primary energy-producing organelles, mitochondria generate the majority of cellular ATP, and the preservation of their functional integrity is essential for cellular viability (29). Through the recognition and removal of damaged or dysfunctional mitochondria, mitophagy sustains cellular energy homeostasis and metabolic equilibrium, while mitigating the accumulation of oxidative stress (30).
Currently, mitophagy is thought to proceed primarily through two distinct pathways: mitochondrial membrane receptor–mediated signaling and the PINK1/Parkin pathway. In the receptor-dependent mechanism, proteins such as BNIP3, NIX, and FUNDC1 located on the outer mitochondrial membrane directly interact with the autophagy-associated protein LC3, enabling damaged mitochondria to be selectively sequestered into autophagosomes. This process is relatively straightforward and is commonly activated under hypoxic or cellular stress conditions (31, 32).
The PINK1/Parkin pathway represents the more classical mechanism. When mitochondrial membrane potential declines, PINK1 is unable to translocate into the matrix and consequently accumulates on the outer membrane, where it recruits the E3 ubiquitin ligase Parkin. Parkin ubiquitinates multiple outer mitochondrial membrane proteins, thereby facilitating the recruitment of autophagy receptors such as p62, NDP52, and OPTN to mediate autophagosome formation. Through this cascade, cells identify and remove dysfunctional mitochondria, thereby preventing excessive accumulation of reactive oxygen species and preserving mitochondrial quality control and metabolic homeostasis (33, 34). As shown in Figure 1, mitophagy occurs through the PINK1/Parkin pathway, where damaged mitochondria are identified and removed by the autophagic machinery.
Figure 1. The mechanism of mitophagy. Legend of Figure 1: This figure illustrates the mechanism of mitophagy through the PINK1/Parkin pathway. Damaged mitochondria are recognized through the accumulation of ROS, which activates PINK1. PINK1 then recruits Parkin, marking the damaged mitochondria for degradation. LC3 plays a role in the formation of autophagosomes, which eventually fuse with lysosomes for mitochondrial degradation. This process helps maintain cellular energy metabolism and overall cell function.
Furthermore, mitophagy is intricately regulated by multiple metabolic signaling pathways, including mTOR, AMPK, and the Sirtuin family, which collectively sense cellular energy status and stress levels. AMPK activation generally promotes the initiation of autophagy by suppressing mTORC1 activity, whereas Sirtuin-mediated deacetylation modulates the function of key autophagy regulators (such as PGC-1α and FOXO3a), thereby indirectly influencing the dynamic balance between mitochondrial biogenesis and clearance (35–37). Overall, mitophagy serves not only as a quality control mechanism for the removal of damaged mitochondria but also as a pivotal regulatory node linking energy metabolism, redox homeostasis, and immune responses.
4 Mitochondrial isolation and autophagy assessment methods
Mitochondria, as critical organelles, directly influence cellular homeostasis and disease development through their structural and functional integrity. Accurate investigation of mitochondrial function and associated autophagy processes requires the isolation of high-purity, structurally intact mitochondrial preparations. Currently, commonly employed isolation techniques include differential centrifugation, density gradient centrifugation, immunomagnetic bead-based separation, and fluorescent labeling. As shown in Figure 2, various methods for mitochondrial isolation are commonly employed to purify mitochondria for further analysis.
Figure 2. Methods for mitochondrial isolation. Legend of Figure 2: This figure summarizes four commonly used methods for mitochondrial isolation: differential centrifugation, density gradient centrifugation, immunomagnetic bead separation, and fluorescence labeling. Each method has its own advantages in terms of purity and specificity, depending on the experimental needs.
Differential centrifugation is widely employed for isolating mitochondria from routine cell or tissue samples due to its simplicity and high reproducibility, although its purity and structural integrity are relatively limited (38). Density gradient centrifugation can further enhance resolution and purity, making it suitable for the more precise separation of mitochondrial subpopulations (39). Immunomagnetic bead-based separation utilizes specific antibodies for rapid and selective enrichment, but it is costly and heavily dependent on antibody quality (40). Fluorescent labeling is frequently applied in live-cell experiments to dynamically monitor changes in mitochondrial morphology and distribution, although it may partially interfere with normal mitochondrial function (41). Consequently, researchers must select the most appropriate isolation method according to the study objectives, sample type, and experimental conditions.
The evaluation of mitophagy encompasses a variety of experimental approaches. Fluorescence microscopy can visually capture the interaction between mitochondria and autophagosomes and remains one of the most commonly employed observation techniques, although its quantitative capacity is limited (42). Western blot analysis of autophagy-related markers (such as LC3 and P62) provides robust quantitative assessment of autophagic activity (43). Flow cytometry is valued for its high throughput and sensitivity, making it suitable for population-level functional analyses (44). Electron microscopy allows direct visualization of mitochondrial ultrastructural changes and is regarded as a critical method for confirming autophagy, though it requires stringent experimental conditions and advanced technical skills (45). Additionally, measurements of oxygen consumption rate (OCR) or cellular ATP content are frequently employed to indirectly evaluate mitochondrial functional status.
In summary, different mitochondrial isolation and autophagy assessment techniques possess distinct characteristics in terms of sensitivity, specificity, and operational complexity, and their selection should be carefully considered based on the research objectives and experimental requirements. For structural and functional analyses, density gradient centrifugation and electron microscopy are particularly suited for detailed investigation, whereas fluorescent labeling and flow cytometry offer advantages for dynamic monitoring or high-throughput screening. Immunomagnetic bead-based separation is well-suited for targeted studies of specific cell populations or mitochondrial subpopulations. The judicious selection and combination of multiple methods can not only enhance the reliability of experimental results but also provide a more comprehensive understanding of the relationship between mitochondrial function and autophagy regulation.
5 Mechanisms of mitophagy in GITs cells
Mitophagy plays a pivotal role in maintaining cellular homeostasis, energy metabolism, and immune responses, which are crucial for various aspects of tumor cell behavior, including growth, migration, invasion, drug resistance, and immune evasion. By regulating redox balance, cellular metabolism, and interactions within the tumor microenvironment, mitophagy determines the survival capacity of tumor cells. As shown in Figure 3, mitophagy plays a crucial role in regulating key cellular processes, including cell generation, apoptosis, drug resistance, tumor migration, and microenvironment modulation.
Figure 3. The role of mitophagy in various cellular processes. Legend of Figure 3: This figure illustrates the diverse roles of mitophagy in regulating several cellular processes. It shows how mitophagy participates in cell generation and development, apoptosis, drug resistance, microenvironment regulation, and tumor migration/invasion.
5.1 Cell generation and development
The generation and development of GITs cells are often accompanied by metabolic changes. Mitophagy contributes to maintaining metabolic balance in tumor cells by removing damaged mitochondria, reducing the accumulation of ROS, and preventing cell death caused by mitochondrial dysfunction (46, 47). Mechanistically, when mitochondria are damaged, PINK1 accumulates and recruits Parkin, initiating the mitophagy process. Mitophagy not only removes damaged mitochondria but also maintains ATP supply and regulates ROS levels, promoting tumor cell proliferation in hypoxic and nutrient-deprived environments (48, 49). BNIP3 and NIX are key regulators of mitophagy. By binding to autophagosomes or interacting with other intracellular structures, they facilitate the fusion of damaged mitochondria with autophagosomes (50–52).
Additionally, mitophagy regulates fatty acid oxidation pathways, reduces endogenous ROS production, sustains energy supply, and supports tumor cell proliferation (53, 54). Inhibition of mitophagy significantly suppresses tumor growth and increases ROS levels, underscoring the importance of mitophagy in tumor progression (55). Clinical studies have also found that enhanced mitophagy is closely associated with tumor proliferation in colorectal cancer patients. This mechanism helps maintain cellular metabolic stability and energy balance, supporting tumor cell growth (56–58).
5.2 Cell apoptosis
Apoptosis is a core mechanism for maintaining tissue homeostasis and eliminating damaged or potentially malignant cells, and it plays an important role in suppressing cancer during the early stages of tumor development. However, many tumors suppress apoptosis by downregulating death-receptor pathways, upregulating anti-apoptotic proteins, or inhibiting p53 signaling, thereby acquiring the ability to proliferate continuously and evade immune surveillance (59). In gastrointestinal tumors, the relationship between mitophagy and apoptosis is particularly complex, and its dysregulation often directly influences cell fate.
Current studies have shown that mitophagy inhibits oxidative stress-induced cell death by reducing ROS levels (60). However, in certain cases, the inhibition of mitophagy may result in the accumulation of damaged mitochondria, which in turn activates endogenous stress signals such as AMPK and p53, prompting cells to enter an apoptotic state (61–63). When cells are in a low-energy state, the AMPK pathway is activated, inhibiting the mTORC1 signaling pathway, which enhances mitophagy and prevents cell death due to energy deficiency (64–66). p53 can upregulate BNIP3, promoting mitophagy to remove damaged mitochondria and prevent apoptosis (67, 68). Additionally, p53 regulates mitochondrial outer membrane permeability, releasing cytochrome C and modulating both mitophagy and the Caspase-3 pathway to maintain cellular stability (69, 70).
In a mouse model of breast cancer, inhibition of mitophagy leads to increased ROS levels, activation of p53, and induction of tumor cell apoptosis (71). In another experiment, p53 promoted mitophagy by upregulating BNIP3 while reducing the accumulation of ROS in mitochondria (72). Clinical observations have indicated that in breast cancer patients, tumor cells with higher levels of mitophagy exhibit longer survival, suggesting that mitophagy helps inhibit tumor cell apoptosis and improves drug resistance (73, 74).
5.3 Cellular drug resistance
Tumor cell drug resistance remains a significant challenge in cancer treatment. Mitochondria supply energy to tumor cells, prevent cellular dysfunction, and contribute to the enhancement of drug resistance. SIRT1, a deacetylase and a member of the sirtuin family, is widely distributed in cells, particularly within the nucleus and cytoplasm (75). Mitophagy can upregulate SIRT1 expression through the regulation of oxidative stress and other mechanisms, thus influencing aging-related genes to delay cellular aging (76, 77). Additionally, SIRT1 plays a key role in regulating cellular energy status and metabolic pathways, and participates in DNA repair processes, enabling tumor cells to survive under drug-induced stress (78–80). Furthermore, mitophagy amplifies tumor cell drug resistance by modulating fatty acid oxidation and ATP production (81, 82).
Studies have shown that cisplatin can cause mitochondrial damage in tumor cells, activating mitophagy, lowering ROS levels, and sustaining ATP production, which increases the cells’ resistance to cisplatin toxicity (83, 84). Likewise, doxorubicin can induce autophagy via mitochondrial damage, helping tumor cells evade drug-induced apoptosis (85).
In mouse models of colorectal cancer, inhibition of mitophagy significantly reduced tumor cell resistance to chemotherapy and increased their sensitivity to chemotherapeutic agents (86). Clinical studies have shown that specific inhibition of SIRT1 can notably enhance the efficacy of chemotherapy and effectively reverse resistance in lung cancer treatment (87). Furthermore, studies in some colorectal cancer patients have revealed that enhanced mitophagy is closely associated with chemotherapy resistance. Therefore, inhibiting mitophagy may represent an effective strategy for overcoming drug resistance (88).
5.4 Cell migration and invasion
Similarly, tumor cell migration and invasion are critical processes in tumor metastasis. Mitophagy promotes tumor cell migration and invasion by regulating the activity of related enzymes and signaling pathways. GTPases such as RhoA, RhoB, and RhoC regulate cell morphology, adhesion, and migratory ability, and are involved in tumor metastasis (89, 90). Mitophagy facilitates tumor cell migration and invasion by modulating the activity of Rho GTPases and remodeling the cytoskeleton (91).
Furthermore, when mitophagy is enhanced, the Wnt signaling pathway is activated, promoting tumor cell adhesion and motility, thereby increasing invasiveness (92, 93). In a lung cancer model, inhibition of mitophagy significantly reduced tumor cell migration and invasion (94). In a liver cancer model, promoting mitophagy regulates the activity of Rho GTPases, enhancing the invasive ability of tumor cells (95).
5.5 Regulation of the tumor microenvironment
The tumor microenvironment (TME) plays a central regulatory role in tumor initiation and progression. The TME consists of tumor cells, fibroblasts, immune cells, vascular endothelial cells, the extracellular matrix, and various soluble factors. Its internal components influence tumor behavior through continuous and dynamic interactions (96). Studies have shown that the TME not only provides structural support and biochemical cues for tumor cells, but also sustains tumor growth by regulating inflammation, promoting angiogenesis, inducing immunosuppression, and driving invasion and metastasis (97). Further research indicates that ammonia, as an important metabolic regulator, can directly influence the immune microenvironment and thereby modulate anti-tumor immune function (98).
Mitophagy also regulates the metabolic state of immune cells, influencing their functIn GITs, the tumor microenvironment plays a pivotal role.
Mitophagy not only enhances the resistance of tumor cells by modulating the interactions between immune cells and tumor cells, but also prevents the excessive activation of immune cells such as dendritic cells and macrophages, thereby facilitating immune evasion by the tumor (16, 99, 100).
Mitophagy plays an important role in tumor immune escape, involving multiple signaling pathways. For instance, PINK1/Parkin-mediated mitophagy helps maintain mitochondrial homeostasis, limits ROS accumulation, and suppresses immune cell activation and the release of inflammatory factors. The mTOR/AMPK pathway influences anti-tumor immune responses by modulating the metabolic state and effector functions of T cells and macrophages. Additionally, the NF-κB/STAT3 pathway can dampen immune responses and promote tumor immune escape by controlling the expression of immunosuppressive factors (101, 102). Together, these findings indicate that mitophagy shapes immune cell function and contributes to tumor immune tolerance in the tumor microenvironment through the coordinated regulation of metabolic and signaling networks. In animal studies, blocking mitophagy has been shown to strengthen anti-tumor immune responses and improve the effects of immunotherapy (103). Clinical observations also suggest that tumors with higher mitophagy levels tend to exhibit stronger immune escape capabilities (104).
6 The role and challenges of mitophagy in different GITs cells
Different tumor cell types, such as gastric epithelial cells, intestinal epithelial cells, and tumor-associated fibroblasts, play distinct roles within the tumor microenvironment. However, they all utilize the same mitophagy mechanisms to collectively regulate key processes of tumor growth, drug resistance, metastasis, and immune escape. For a detailed description of the molecular pathways, mechanisms of action, and animal and clinical trial data, please refer to Table 2. As shown in Figure 4, the PINK1/Parkin activator enhances treatment sensitivity and reduces tumor growth and metastasis, while the BNIP3/NIX inhibitor promotes cell survival and drug resistance, facilitating tumor progression.
Table 2. Mitophagy in different gastrointestinal tumor cell types: mechanisms, roles, and challenges.
Figure 4. Impact of PINK1/Parkin activator and BNIP3/NIX inhibitor on tumor growth and metastasis. Legend of Figure 4: This figure illustrates the contrasting effects of PINK1/Parkin activators and BNIP3/NIX inhibitors on tumor progression. Activation of the PINK1/Parkin pathway increases cell death, reduces ROS levels, and enhances treatment sensitivity, leading to decreased tumor growth and metastasis. Conversely, inhibition of BNIP3 and NIX enhances cell survival and drug resistance, promoting tumor growth and metastasis.
6.1 Therapeutic potential of mitophagy
Mitophagy exhibits a classic “double-edged sword” effect in the pathogenesis and treatment of GITs. On one hand, mitophagy provides a survival advantage to tumor cells by removing damaged mitochondria, maintaining cellular energy metabolism, and reducing oxidative stress levels. Under stress conditions such as chemotherapy and radiotherapy, tumor cells can activate mitophagy through pathways such as PINK1/Parkin, BNIP3, or FUNDC1 to counteract the damage caused by drugs and radiation, leading to the development of resistance. Moreover, excessive reliance on mitophagy may impair immune cell function and promote tumor immune escape.
On the other hand, mitophagy can exert anti-cancer effects in certain contexts. In the early stages of tumorigenesis, moderate mitophagy helps eliminate potentially oncogenic organelles, reduces DNA damage, and mitigates the risk of genetic mutations, thus halting the carcinogenesis process. Furthermore, certain drugs or natural products can induce energy crisis and cell death by excessively activating mitophagy, thereby directly inhibiting GITs cells. For example, melatonin induces tumor cell apoptosis by activating mitophagy and promoting ROS accumulation (132). Bafilomycin, when combined with chemotherapeutic agents, enhances tumor cell death by inhibiting the fusion of autophagosomes and lysosomes, producing a synergistic effect (133). Nuciferine inhibits mitophagy by blocking autophagosome–lysosome fusion, thereby increasing the sensitivity of tumor cells to chemotherapy-induced death (134). Ketoconazole and mitochondria-targeted metformin (Mito-Metformin) trigger mitophagy through regulation of the PINK1/Parkin pathway, leading to suppressed tumor cell proliferation (135, 136). In addition, andrographolide, a natural antioxidant, and EGCG, a polyphenolic catechin from green tea, show strong antitumor activity in colon cancer (137).
More importantly, regulating mitophagy in immune cells can restore their metabolic activity and effector functions, enhancing the anti-tumor effects of immunotherapy. Therefore, mitophagy in GITs may serve both as a “protective shield” promoting tumor survival and as a “nemesis” that induces tumor cell apoptosis and boosts immune effects. The key challenge in the future is how to precisely modulate mitophagy in different clinical settings to optimize GITs treatment strategies.
Mitophagy-based treatment strategies have demonstrated considerable effectiveness in GITs. Combining these approaches with conventional therapies could further optimize treatment outcomes. Research indicates that when tumor cells activate mitophagy, their resistance to standard treatments is significantly heightened (138). Therefore, inhibiting mitophagy may serve as an effective strategy to overcome tumor drug resistance. Combining mitophagy inhibitors with chemotherapy or radiotherapy can strengthen the cytotoxic effects of these treatments, help reverse resistance, and ultimately improve therapeutic efficacy and patient survival.
Immunotherapy has brought notable progress to the treatment of gastrointestinal tumors, but its effectiveness is still limited by the complex regulation of the immune microenvironment. Mitophagy, a key process that sustains the metabolic balance and functional activity of immune cells, is now gaining attention as a potential target for immunotherapy. Appropriate levels of mitophagy help remove damaged mitochondria and maintain T-cell energy metabolism and cytotoxic activity; however, disruption of autophagy balance can result in metabolic reprogramming disorders and immune exhaustion, which weaken the anti-tumor immune response. For example, several studies have shown that activation of the PINK1/Parkin pathway supports mitochondrial quality control in CD8+ T cells and enhances their ability to kill tumor cells (139). In contrast, excessive mitophagy can lead to energy depletion in antigen-presenting cells and increased PD-1 expression, thereby promoting immune escape (140, 141). Moreover, tumor cells may evade immune recognition by upregulating mitophagy receptors such as BNIP3 and FUNDC1, leading to a state of immune tolerance (142, 143). Previous studies have also indicated that regulating mitophagy in combination with immune checkpoint therapy can significantly improve therapeutic outcomes in tumor treatment (144). Therefore, targeting mitophagy may offer new perspectives for improving the response to immunotherapy.
6.2 Challenges of mitophagy in clinical applications
Currently, clinical research on mitophagy in gastrointestinal tumors is still in its early stages, with most studies relying on in vitro experiments and animal models. Although a small number of observational studies have explored its role in tumor prognosis and immune therapy response, there is a lack of systematic interventional studies and large-scale clinical trials.
Although mitophagy is increasingly recognized for its potential in treating GITs, significant obstacles remain in its clinical application. As a self-regulatory mechanism within cells, the activity of mitophagy must be carefully balanced. Both excessive suppression and overstimulation can lead to undesirable effects, particularly regarding cellular energy supply and metabolic stability. While some mitophagy modulators have shown promising results in early studies, a comprehensive assessment of their long-term effects, management of potential side effects, and ensuring their clinical safety are essential for successful implementation in clinical practice.
7 Conclusion and future perspectives
Mitophagy plays a crucial role in the development, progression, drug resistance, and immune evasion of GITs. By regulating mitophagy, tumor cells can adapt to adverse conditions such as hypoxia and nutrient deprivation, maintain metabolic stability, and promote proliferation and metastasis. Additionally, mitophagy influences tumor immune evasion pathways by modulating immune cell activity, thereby facilitating immune escape. Although mitophagy offers a promising theoretical framework for cancer treatment, significant challenges remain in its clinical translation, particularly regarding drug safety, individual treatment variations, and efficacy validation. Future research should focus on the precise regulation of mitophagy, investigate its potential synergistic effects with other therapies, and advance its clinical application in treating GITs.
Author contributions
TZ: Conceptualization, Investigation, Software, Writing – original draft, Writing – review & editing. ZR: Data curation, Methodology, Supervision, Writing – original draft, Writing – review & editing. BT: Data curation, Methodology, Supervision, Writing – original draft. RM: Formal Analysis, Project administration, Validation, Writing – original draft. LW: Writing – review & editing. QW: Funding acquisition, Resources, Visualization, Writing – review & editing. JP: Funding acquisition, Resources, Visualization, Writing – review & editing. YY: Funding acquisition, Resources, Visualization, Writing – review & editing.
Funding
The author(s) declared financial support was received for this work and/or its publication. Liaoning Provincial Department of Science and Technology (2025-BS-0716); Liaoning Provincial Institute of Traditional Chinese Medicine Project (2025JH2/101800405); Liaoning Provincial Department of Education Project (LJ222510162004).
Conflict of interest
The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. GBD 2019 Colorectal Cancer Collaborators. Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. (2022) 7:627–47. doi: 10.1016/S2468-1253(22)00044-9
2. Li M, Cao S, and Xu RH. Global trends and epidemiological shifts in gastrointestinal cancers: insights from the past four decades. Cancer Commun (Lond). (2025) 45:774–88. doi: 10.1002/cac2.70017
3. Morgan E, Arnold M, Camargo MC, Gini A, Kunzmann AT, Matsuda T, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study. EClinicalMedicine. (2022) 47:101404. doi: 10.1016/j.eclinm.2022.101404
4. Huang J, Lucero-Prisno DE III, Zhang L, Xu W, Wong SH, Ng SC, et al. Updated epidemiology of gastrointestinal cancers in East Asia. Nat Rev Gastroenterol Hepatol. (2023) 20:271–87. doi: 10.1038/s41575-022-00726-3
5. Zhang X, Gao B, and Wang W. Early-onset gastric cancer global burden profile, trends, and contributors. Cancer Biol Med. (2025). doi: 10.20892/j.issn.2095-3941.2025.0320
6. Henderson RH, French D, Maughan T, Adams R, Allemani C, Minicozzi P, et al. The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study. Lancet Gastroenterol Hepatol. (2021) 6:709–22. doi: 10.1016/S2468-1253(21)00147-3
7. Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. (2023) 72:338–44. doi: 10.1136/gutjnl-2022-327736
8. Kitaw TA, Tilahun BD, Zemariam AB, Getie A, Bizuayehu MA, and Haile RN. The financial toxicity of cancer: unveiling global burden and risk factors - a systematic review and meta-analysis. BMJ Glob Health. (2025) 10:e017133. doi: 10.1136/bmjgh-2024-017133
9. Joshi SS and Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. (2021) 71:264–79. doi: 10.3322/caac.21657
10. Guan WL, He Y, and Xu RH. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. (2023) 16:57. doi: 10.1186/s13045-023-01451-3
11. Alsina M, Arrazubi V, Diez M, and Tabernero J. Current developments in gastric cancer: from molecular profiling to treatment strategy. Nat Rev Gastroenterol Hepatol. (2023) 20:155–70. doi: 10.1038/s41575-022-00703-w
12. Yasuda T and Wang YA. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development. Trends Cancer. (2024) 10:627–42. doi: 10.1016/j.trecan.2024.03.008
13. Abken H. CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges. Nat Rev Gastroenterol Hepatol. (2025) 22:463–80. doi: 10.1038/s41575-025-01062-y
14. Wang J, Zhang Y, Cao J, Wang Y, Anwar N, Zhang Z, et al. The role of autophagy in bone metabolism and clinical significance. Autophagy. (2023) 19:2409–27. doi: 10.1080/15548627.2023.2186112
15. Ren Y, Wang R, Weng S, Xu H, Zhang Y, Chen S, et al. Multifaceted role of redox pattern in the tumor immune microenvironment regarding autophagy and apoptosis. Mol Cancer. (2023) 22:130. doi: 10.1186/s12943-023-01831-w
16. Xia H, Green DR, and Zou W. Autophagy in tumour immunity and therapy. Nat Rev Cancer. (2021) 21:281–97. doi: 10.1038/s41568-021-00344-2
17. Feng Y, Chen Y, Wu X, Chen J, Zhou Q, Liu B, et al. Interplay of energy metabolism and autophagy. Autophagy. (2024) 20:4–14. doi: 10.1080/15548627.2023.2247300
18. Zheng Y, Huang C, Lu L, Yu K, Zhao J, Chen M, et al. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib. J Hematol Oncol. (2021) 14:16. doi: 10.1186/s13045-020-01029-3
19. Haque PS, Kapur N, Barrett TA, and Theiss AL. Mitochondrial function and gastrointestinal diseases. Nat Rev Gastroenterol Hepatol. (2024) 21:537–55. doi: 10.1038/s41575-024-00931-2
20. Liu AR, Lv Z, Yan ZW, Wu XY, Yan LR, Sun LP, et al. Association of mitochondrial homeostasis and dynamic balance with Malignant biological behaviors of gastrointestinal cancer. J Transl Med. (2023) 21:27. doi: 10.1186/s12967-023-03878-1
21. Li GZ, Doherty GM, and Wang J. Surgical Management of Gastric Cancer: A Review. JAMA Surg. (2022) 157:446–454. doi: 10.1001/jamasurg.2022.0182
22. Yang T and Guo L. Advancing gastric cancer treatment: nanotechnology innovations and future prospects. Cell Biol Toxicol. (2024) 40:101. doi: 10.1007/s10565-024-09943-9
23. Eslami M, Memarsadeghi O, Davarpanah A, Arti A, Nayernia K, and Behnam B. Overcoming chemotherapy resistance in metastatic cancer: A comprehensive review. Biomedicines. (2024) 12:183. doi: 10.3390/biomedicines12010183
24. Andreyev J, Adams R, Bornschein J, Chapman M, Chuter D, Darnborough S, et al. British Society of Gastroenterology practice guidance on the management of acute and chronic gastrointestinal symptoms and complications as a result of treatment for cancer. Gut. (2025) 74:1040–67. doi: 10.1136/gutjnl-2024-333812
25. Du YX, Li X, Ji SW, and Niu N. Hypertension toxicity of VEGFR-TKIs in cancer treatment: incidence, mechanisms, and management strategies. Arch Toxicol. (2025) 99:67–81. doi: 10.1007/s00204-024-03874-4
26. He J, Chen Y, Zhao H, and Li Y. The interplay between gut bacteria and targeted therapies: implications for future cancer treatments. Mol Med. (2025) 31:58. doi: 10.1186/s10020-025-01108-6
27. Deng Z, Luo Y, Chen X, Pan T, Rui Y, Hu H, et al. Pathological response following neoadjuvant immunotherapy and imaging characteristics in dMMR/MSI-H locally advanced colorectal cancer. Front Immunol. (2024) 15:1466497. doi: 10.3389/fimmu.2024.1466497
28. Mitra A, Kumar A, Amdare NP, and Pathak R. Current landscape of cancer immunotherapy: harnessing the immune arsenal to overcome immune evasion. Biol (Basel). (2024) 13:307. doi: 10.3390/biology13050307
29. He C. Balancing nutrient and energy demand and supply via autophagy. Curr Biol. (2022) 32:R684–96. doi: 10.1016/j.cub.2022.04.071
30. Borcherding N and Brestoff JR. The power and potential of mitochondria transfer. Nature. (2023) 623:283–91. doi: 10.1038/s41586-023-06537-z
31. Wang L, Zhou X, and Lu T. Role of mitochondria in physiological activities, diseases, and therapy. Mol Biomed. (2025) 6:42. doi: 10.1186/s43556-025-00284-5
32. D’Arcy MS. Mitophagy in health and disease. Molecular mechanisms, regulatory pathways, and therapeutic implications. Apoptosis. (2024) 29:1415–28. doi: 10.1007/s10495-024-01977-y
33. Narendra DP and Youle RJ. The role of PINK1-Parkin in mitochondrial quality control. Nat Cell Biol. (2024) 26:1639–51. doi: 10.1038/s41556-024-01513-9
34. Di Rienzo M, Romagnoli A, Ciccosanti F, Refolo G, Consalvi V, Arena G, et al. AMBRA1 regulates mitophagy by interacting with ATAD3A and promoting PINK1 stability. Autophagy. (2022) 18:1752–62. doi: 10.1080/15548627.2021.1997052
35. Cabrera-Serrano AJ, Sánchez-Maldonado JM, González-Olmedo C, Carretero-Fernández M, Díaz-Beltrán L, Gutiérrez-Bautista JF, et al. Crosstalk between autophagy and oxidative stress in hematological Malignancies: mechanisms, implications, and therapeutic potential. Antioxidants (Basel). (2025) 14:264. doi: 10.3390/antiox14030264
36. Zhang T, Liu Q, Gao W, Sehgal SA, and Wu H. The multifaceted regulation of mitophagy by endogenous metabolites. Autophagy. (2022) 18:1216–39. doi: 10.1080/15548627.2021.1975914
37. Xu W, Luo Y, Yin J, Huang M, and Luo F. Targeting AMPK signaling by polyphenols: a novel strategy for tackling aging. Food Funct. (2023) 14:56–73. doi: 10.1039/d2fo02688k
38. Xu W, Luo Y, Yin J, Huang M, and Luo F. Human neural stem cell-derived artificial organelles to improve oxidative phosphorylation. Nat Commun. (2024) 15:7855. doi: 10.1038/s41467-024-52171-2
39. Ma T, Tian X, Zhang B, Li M, Wang Y, Yang C, et al. Low-dose metformin targets the lysosomal AMPK pathway through PEN2. Nature. (2022) 603:159–65. doi: 10.1038/s41586-022-04431-8
40. Ajmal R, Zhang W, Liu H, Bai H, Cao L, Peng B, et al. Development of a microfluidic system for mitochondrial extraction, purification, and analysis. ACS Appl Mater Interfaces. (2025) 17:20487–500. doi: 10.1021/acsami.4c18415
41. Chen C, Li H, Zhang J, and Cheng SC. Exploring the limitations of mitochondrial dye as a genuine horizontal mitochondrial transfer surrogate. Commun Biol. (2024) 7:281. doi: 10.1038/s42003-024-05964-6
42. Li X, Liang X, Yin J, and Lin W. Organic fluorescent probes for monitoring autophagy in living cells. Chem Soc Rev. (2021) 50:102–19. doi: 10.1039/d0cs00896f
43. Magalhaes-Novais S, Blecha J, Naraine R, Mikesova J, Abaffy P, Pecinova A, et al. Mitochondrial respiration supports autophagy to provide stress resistance during quiescence. Autophagy. (2022) 18:2409–26. doi: 10.1080/15548627.2022.2038898
44. Wang B, Dai L, Liang H, He J, Zhou J, Guan Y, et al. Mitochondrial ultrastructural pathology in diabetic cardiomyopathy: integrated analysis via scanning electron microscopy and 3D visualization imaging. Cardiovasc Diabetol. (2025) 24:331. doi: 10.1186/s12933-025-02884-5
45. Zong Y, Li H, Liao P, Chen L, Pan Y, Zheng Y, et al. Mitochondrial dysfunction: mechanisms and advances in therapy. Signal Transduct Target Ther. (2024) 9:124. doi: 10.1038/s41392-024-01839-8
46. Zhang L, Zhang W, Li Z, Lin S, Zheng T, Hao B, et al. Mitochondria dysfunction in CD8+ T cells as an important contributing factor for cancer development and a potential target for cancer treatment: a review. J Exp Clin Cancer Res. (2022) 41:227. doi: 10.1186/s13046-022-02439-6
47. Kuo CL, Ponneri Babuharisankar A, Lin YC, Lien HW, Lo YK, Chou HY, et al. Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend? J BioMed Sci. (2022) 29:74. doi: 10.1186/s12929-022-00859-2
48. Goul C, Peruzzo R, and Zoncu R. The molecular basis of nutrient sensing and signalling by mTORC1 in metabolism regulation and disease. Nat Rev Mol Cell Biol. (2023) 24:857–75. doi: 10.1038/s41580-023-00641-8
49. Park JM, Lee DH, and Kim DH. Redefining the role of AMPK in autophagy and the energy stress response. Nat Commun. (2023) 14:2994. doi: 10.1038/s41467-023-38401-z
50. Yamashita SI, Sugiura Y, Matsuoka Y, Maeda R, Inoue K, Furukawa K, et al. Mitophagy mediated by BNIP3 and NIX protects against ferroptosis by downregulating mitochondrial reactive oxygen species. Cell Death Differ. (2024) 31:651–61. doi: 10.1038/s41418-024-01280-y
51. Madhu V, Hernandez-Meadows M, Boneski PK, Qiu Y, Guntur AR, Kurland IJ, et al. The mitophagy receptor BNIP3 is critical for the regulation of metabolic homeostasis and mitochondrial function in the nucleus pulposus cells of the intervertebral disc. Autophagy. (2023) 19:1821–43. doi: 10.1080/15548627.2022.2162245
52. Vianello C, Cocetta V, Catanzaro D, Dorn GW II, De Milito A, Rizzolio F, et al. Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy. Cell Death Dis. (2022) 13:398. doi: 10.1038/s41419-022-04741-9
53. Zhou J, Li XY, Liu YJ, Feng J, Wu Y, Shen HM, et al. Full-coverage regulations of autophagy by ROS: from induction to maturation. Autophagy. (2022) 18:1240–55. doi: 10.1080/15548627.2021.1984656
54. Castelli S, Ciccarone F, Tavian D, and Ciriolo MR. ROS-dependent HIF1α activation under forced lipid catabolism entails glycolysis and mitophagy as mediators of higher proliferation rate in cervical cancer cells. J Exp Clin Cancer Res. (2021) 40:94. doi: 10.1186/s13046-021-01887-w
55. Li Y, Shang C, Liu Z, Han J, Li W, Xiao P, et al. Apoptin mediates mitophagy and endogenous apoptosis by regulating the level of ROS in hepatocellular carcinoma. Cell Commun Signal. (2022) 20:134. doi: 10.1186/s12964-022-00940-1
56. Devenport SN, Singhal R, Radyk MD, Taranto JG, Kerk SA, Chen B, et al. Colorectal cancer cells utilize autophagy to maintain mitochondrial metabolism for cell proliferation under nutrient stress. JCI Insight. (2021) 6:e138835. doi: 10.1172/jci.insight.138835
57. Wu Z, Xiao C, Long J, Huang W, You F, Li X, et al. Mitochondrial dynamics and colorectal cancer biology: mechanisms and potential targets. Cell Commun Signal. (2024) 22:91. doi: 10.1186/s12964-024-01490-4
58. Liu J, Wu Y, Meng S, Xu P, Li S, Li Y, et al. Selective autophagy in cancer: mechanisms, therapeutic implications, and future perspectives. Mol Cancer. (2024) 23:22. doi: 10.1186/s12943-024-01934-y
59. Gupta N, Abd El-Gawaad NS, Mallasiy LO, Alghamdi S, and Yadav VK. Hydrogen: an advanced and safest gas option for cancer treatment. Med Gas Res. (2025) 15:191–2. doi: 10.4103/mgr.MEDGASRES-D-24-00082
60. Chang KC, Liu PF, Chang CH, Lin YC, Chen YJ, and Shu CW. The interplay of autophagy and oxidative stress in the pathogenesis and therapy of retinal degenerative diseases. Cell Biosci. (2022) 12:1. doi: 10.1186/s13578-021-00736-9
61. Gupta R, Ambasta RK, and Kumar P. Autophagy and apoptosis cascade: which is more prominent in neuronal death? Cell Mol Life Sci. (2021) 78:8001–47. doi: 10.1007/s00018-021-04004-4
62. Liu Y, Stockwell BR, Jiang X, and Gu W. p53-regulated non-apoptotic cell death pathways and their relevance in cancer and other diseases. Nat Rev Mol Cell Biol. (2025) 26:600–14. doi: 10.1038/s41580-025-00842-3
63. Song C, Pan S, Zhang J, Li N, and Geng Q. Mitophagy: A novel perspective for insighting into cancer and cancer treatment. Cell Prolif. (2022) 55:e13327. doi: 10.1111/cpr.13327
64. Li YY, Qin ZH, and Sheng R. The multiple roles of autophagy in neural function and diseases. Neurosci Bull. (2024) 40:363–82. doi: 10.1007/s12264-023-01120-y
65. Chen X, Ji Y, Liu R, Zhu X, Wang K, Yang X, et al. Mitochondrial dysfunction: roles in skeletal muscle atrophy. J Transl Med. (2023) 21:503. doi: 10.1186/s12967-023-04369-z
66. Zeng F, Cao J, Li W, Zhou Y, and Yuan X. FNIP1: A key regulator of mitochondrial function. BioMed Pharmacother. (2024) 177:117146. doi: 10.1016/j.biopha.2024.117146
67. Chen Y, Yang F, Shi Y, Sheng J, Wang Y, Zhang L, et al. RNF31 alleviates liver steatosis by promoting p53/BNIP3-related mitophagy in hepatocytes. Free Radic Biol Med. (2024) 219:163–79. doi: 10.1016/j.freeradbiomed.2024.04.214
68. Mustafa M, Ahmad R, Tantry IQ, Ahmad W, Siddiqui S, Alam M, et al. Apoptosis: A comprehensive overview of signaling pathways, morphological changes, and physiological significance and therapeutic implications. Cells. (2024) 13:1838. doi: 10.3390/cells13221838
69. Das S, Shukla N, Singh SS, Kushwaha S, and Shrivastava R. Mechanism of interaction between autophagy and apoptosis in cancer. Apoptosis. (2021) 26:512–33. doi: 10.1007/s10495-021-01687-9
70. Voronina MV, Frolova AS, Kolesova EP, Kuldyushev NA, Parodi A, and Zamyatnin AA Jr. The intricate balance between life and death: ROS, cathepsins, and their interplay in cell death and autophagy. Int J Mol Sci. (2024) 25:4087. doi: 10.3390/ijms25074087
71. Cruz-Gregorio A, Aranda-Rivera AK, Aparicio-Trejo OE, Medina-Campos ON, Sciutto E, Fragoso G, et al. GK-1 induces oxidative stress, mitochondrial dysfunction, decreased membrane potential, and impaired autophagy flux in a mouse model of breast cancer. Antioxidants (Basel). (2022) 12:56. doi: 10.3390/antiox12010056
72. Ding X, Cui L, Mi Y, Hu J, Cai Z, Tang Q, et al. Ferroptosis in cancer: revealing the multifaceted functions of mitochondria. Cell Mol Life Sci. (2025) 82:277. doi: 10.1007/s00018-025-05812-8
73. Bartlome S and Berry CC. Recent insights into the effects of metabolism on breast cancer cell dormancy. Br J Cancer. (2022) 127:1385–93. doi: 10.1038/s41416-022-01869-5
74. Finnegan RM, Elshazly AM, Schoenlein PV, and Gewirtz DA. Therapeutic potential for targeting autophagy in ER+ Breast cancer. Cancers (Basel). (2022) 14:4289. doi: 10.3390/cancers14174289
75. Yapryntseva MA, Maximchik PV, Zhivotovsky B, and Gogvadze V. Mitochondrial sirtuin 3 and various cell death modalities. Front Cell Dev Biol. (2022) 10:947357. doi: 10.3389/fcell.2022.947357
76. Shen H, Qi X, Hu Y, Wang Y, Zhang J, Liu Z, et al. Targeting sirtuins for cancer therapy: epigenetics modifications and beyond. Theranostics. (2024) 14:6726–67. doi: 10.7150/thno.100667
77. Huang X, Zhao L, and Peng R. Hypoxia-inducible factor 1 and mitochondria: an intimate connection. Biomolecules. (2022) 13:50. doi: 10.3390/biom13010050
78. Bao X, Zhang J, Huang G, Yan J, Xu C, Dou Z, et al. The crosstalk between HIFs and mitochondrial dysfunctions in cancer development. Cell Death Dis. (2021) 12:215. doi: 10.1038/s41419-021-03505-1
79. Wang XW, Jiang YH, Ye W, Shao CF, Xie JJ, and Li X. SIRT1 promotes the progression and chemoresistance of colorectal cancer through the p53/miR-101/KPNA3 axis. Cancer Biol Ther. (2023) 24:2235770. doi: 10.1080/15384047.2023.2235770
80. Lei Y, Cai S, Zhang JK, Ding SQ, Zhang ZH, Zhang CD, et al. The role and mechanism of fatty acid oxidation in cancer drug resistance. Cell Death Discov. (2025) 11:277. doi: 10.1038/s41420-025-02554-1
81. Lee H, Woo SM, Jang H, Kang M, and Kim SY. Cancer depends on fatty acids for ATP production: A possible link between cancer and obesity. Semin Cancer Biol. (2022) 86. doi: 10.1016/j.semcancer.2022.07.005
82. Hoy AJ, Nagarajan SR, and Butler LM. Tumour fatty acid metabolism in the context of therapy resistance and obesity. Nat Rev Cancer. (2021) 21:753–66. doi: 10.1038/s41568-021-00388-4
83. Suman I, Šimić L, Čanadi Jurešić G, Buljević S, Klepac D, and Domitrović R. The interplay of mitophagy, autophagy, and apoptosis in cisplatin-induced kidney injury: involvement of ERK signaling pathway. Cell Death Discov. (2024) 10:98. doi: 10.1038/s41420-024-01872-0
84. Wang SF, Chang YL, Liu TY, Huang KH, Fang WL, Li AF, et al. Mitochondrial dysfunction decreases cisplatin sensitivity in gastric cancer cells through upregulation of integrated stress response and mitokine GDF15. FEBS J. (2024) 291:1131–50. doi: 10.1111/febs.16992
85. Zhang Y, Ji Y, Tu Y, and Li Y. Autophagy in doxorubicin resistance: basic concepts, therapeutic perspectives and clinical translation. Front Immunol. (2025) 16:1642050. doi: 10.3389/fimmu.2025.1642050
86. Bahar E, Han SY, Kim JY, and Yoon H. Chemotherapy resistance: role of mitochondrial and autophagic components. Cancers (Basel). (2022) 14:1462. doi: 10.3390/cancers14061462
87. Xu R, Luo X, Ye X, Li H, Liu H, Du Q, et al. SIRT1/PGC-1α/PPAR-γ Correlate with hypoxia-induced chemoresistance in non-small cell lung cancer. Front Oncol. (2021) 11:682762. doi: 10.3389/fonc.2021.682762
88. Mahgoub E, Taneera J, Sulaiman N, and Saber-Ayad M. The role of autophagy in colorectal cancer: Impact on pathogenesis and implications in therapy. Front Med (Lausanne). (2022) 9:959348. doi: 10.3389/fmed.2022.959348
89. Vona R, Mileo AM, and Matarrese P. Microtubule-based mitochondrial dynamics as a valuable therapeutic target in cancer. Cancers (Basel). (2021) 13:5812. doi: 10.3390/cancers13225812
90. Schaefer A and Der CJ. RHOA takes the RHOad less traveled to cancer. Trends Cancer. (2022) 8:655–69. doi: 10.1016/j.trecan.2022.04.005
91. Pradhan R, Ngo PA, Martínez-Sánchez LD, Neurath MF, and López-Posadas R. Rho GTPases as key molecular players within intestinal mucosa and GI diseases. Cells. (2021) 10:66. doi: 10.3390/cells10010066
92. Han J, Yuan Y, Zhang J, Hou Y, Xu H, Nie X, et al. Regulatory effect of Wnt signaling on mitochondria in cancer: from mechanism to therapy. Apoptosis. (2025) 30:1235–52. doi: 10.1007/s10495-025-02114-z
93. Huang Y, Zhang R, Lyu H, Xiao S, Guo D, Chen XZ, et al. LncRNAs as nodes for the cross-talk between autophagy and Wnt signaling in pancreatic cancer drug resistance. Int J Biol Sci. (2024) 20:2698–726. doi: 10.7150/ijbs.91832
94. Xu C, Cao H, Sui Y, Zhang H, Shi C, Wu J, et al. CDCA4 suppresses epithelial-mesenchymal transtion (EMT) and metastasis in Non-small cell lung cancer through modulating autophagy. Cancer Cell Int. (2021) 21:48. doi: 10.1186/s12935-021-01754-w
95. Wang T, Rao D, Yu C, Sheng J, Luo Y, Xia L, et al. RHO GTPase family in hepatocellular carcinoma. Exp Hematol Oncol. (2022) 11:91. doi: 10.1186/s40164-022-00344-4
96. Zhang Y, Fu Q, Sun W, Yue Q, He P, Niu D, et al. Mechanical forces in the tumor microenvironment: roles, pathways, and therapeutic approaches. J Transl Med. (2025) 23:313. doi: 10.1186/s12967-025-06306-8
97. Hu Q, Zhu Y, Mei J, Liu Y, and Zhou G. Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy. J Hematol Oncol. (2025) 18:65. doi: 10.1186/s13045-025-01717-y
98. Zhao L, Lee ZH, and Shah YM. Ammonia as a critical metabolic modulator of anti-tumor immunity. Med Gas Res. (2025) 15:446–7. doi: 10.4103/mgr.MEDGASRES-D-24-00147
99. Marchi S, Guilbaud E, Tait SWG, Yamazaki T, and Galluzzi L. Mitochondrial control of inflammation. Nat Rev Immunol. (2023) 23:159–73. doi: 10.1038/s41577-022-00760-x
100. Deretic V. Autophagy in inflammation, infection, and immunometabolism. Immunity. (2021) 54:437–53. doi: 10.1016/j.immuni.2021.01.018
101. Zhang P, Cheng S, Sheng X, Dai H, He K, and Du Y. The role of autophagy in regulating metabolism in the tumor microenvironment. Genes Dis. (2021) 10:447–56. doi: 10.1016/j.gendis.2021.10.010
102. Wang SF, Tseng LM, and Lee HC. Role of mitochondrial alterations in human cancer progression and cancer immunity. J BioMed Sci. (2023) 30:61. doi: 10.1186/s12929-023-00956-w
103. Xiao H, Li X, Li B, Yang S, Qin J, Han S, et al. Nanodrug inducing autophagy inhibition and mitochondria dysfunction for potentiating tumor photo-immunotherapy. Small. (2023) 19:e2300280. doi: 10.1002/smll.202300280
104. Du F, Yang LH, Liu J, Wang J, Fan L, Duangmano S, et al. The role of mitochondria in the resistance of melanoma to PD-1 inhibitors. J Transl Med. (2023) 21:345. doi: 10.1186/s12967-023-04200-9
105. Tanprasert P, Limpakan Yamada S, Chattipakorn SC, Chattipakorn N, and Shinlapawittayatorn K. Targeting mitochondria as a therapeutic anti-gastric cancer approach. Apoptosis. (2022) 27:163–83. doi: 10.1007/s10495-022-01709-0
106. Nie W, Hu L, Yan Z, Wang Q, He S, Gao X, et al. Study on the regulation of gastric cancer cell apoptosis by LACTB through mitochondrial autophagy pathway. Sci Rep. (2025) 15:23273. doi: 10.1038/s41598-025-06047-0
107. Tsai HY, Tsai KJ, Wu DC, Huang YB, and Lin MW. Transplantation of gastric epithelial mitochondria into human gastric cancer cells inhibits tumor growth and enhances chemosensitivity by reducing cancer stemness and modulating gastric cancer metabolism. Stem Cell Res Ther. (2025) 16:87. doi: 10.1186/s13287-025-04223-7
108. Li Y, Fan B, Pu N, Ran X, Lian T, Cai Y, et al. Isorhamnetin suppresses human gastric cancer cell proliferation through mitochondria-dependent apoptosis. Molecules. (2022) 27:5191. doi: 10.3390/molecules27165191
109. Liu J, Chang Y, Ou Q, Chen L, Yan H, Guo D, et al. Advances in research on the relationship between mitochondrial function and colorectal cancer: a bibliometric study from 2013 to 2023. Front Immunol. (2024) 15:1480596. doi: 10.3389/fimmu.2024.1480596
110. Li Y, Zhu Y, Chu B, Liu N, Chen S, and Wang J. Lactobacillus rhamnosus GR-1 Prevents Escherichia coli-Induced Apoptosis Through PINK1/Parkin-Mediated Mitophagy in Bovine Mastitis. Front Immunol. (2021) 12:715098. doi: 10.3389/fimmu.2021.715098
111. Wang Q, Shen X, Chen G, and Du J. Drug resistance in colorectal cancer: from mechanism to clinic. Cancers (Basel). (2022) 14:2928. doi: 10.3390/cancers14122928
112. Yin K, Lee J, Liu Z, Kim H, Martin DR, Wu D, et al. Mitophagy protein PINK1 suppresses colon tumor growth by metabolic reprogramming via p53 activation and reducing acetyl-CoA production. Cell Death Differ. (2021) 28:2421–35. doi: 10.1038/s41418-021-00760-9
113. Li Z, Sun C, and Qin Z. Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming. Theranostics. (2021) 11:8322–36. doi: 10.7150/thno.62378
114. Zhang L, Wang K, Zhang J, Qian X, Zhang X, Wang Y, et al. PDGFR-β/Cav1-induced autophagy via mTOR/FIP200/ATG13 activation in cancer-associated fibroblasts promotes the Malignant progression of breast cancer. J Transl Med. (2025) 23:784. doi: 10.1186/s12967-025-06831-6
115. Wang S, Liu G, Li Y, and Pan Y. Metabolic reprogramming induces macrophage polarization in the tumor microenvironment. Front Immunol. (2022) 13:840029. doi: 10.3389/fimmu.2022.840029
116. Nishida M, Yamashita N, Ogawa T, Koseki K, Warabi E, Ohue T, et al. Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes. J Immunother Cancer. (2021) 9:e002954. doi: 10.1136/jitc-2021-002954
117. Zhu W, Rao J, Zhang LH, Xue KM, Li L, Li JJ, et al. OMA1 competitively binds to HSPA9 to promote mitophagy and activate the cGAS-STING pathway to mediate GBM immune escape. J Immunother Cancer. (2024) 12:e008718. doi: 10.1136/jitc-2023-008718
118. Yang MQ, Zhang SL, Sun L, Huang LT, Yu J, Zhang JH, et al. Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells. Mol Cancer. (2024) 23:260. doi: 10.1186/s12943-024-02175-9
119. Li L, Zhang Y, Tang Q, Wu C, Yang M, Hu Y, et al. Mitochondria in tumor immune surveillance and tumor therapies targeting mitochondria. Cell Oncol (Dordr). (2024) 47:2031–47. doi: 10.1007/s13402-024-01000-1
120. Shuwen H, Yinhang W, Jing Z, Qiang Y, Yizhen J, Quan Q, et al. Cholesterol induction in CD8+ T cell exhaustion in colorectal cancer via the regulation of endoplasmic reticulum-mitochondria contact sites. Cancer Immunol Immunother. (2023) 72:4441–56. doi: 10.1007/s00262-023-03555-8
121. Li Q, Chen C, Kong J, Li L, Li J, and Huang Y. Stimuli-responsive nano vehicle enhances cancer immunotherapy by coordinating mitochondria-targeted immunogenic cell death and PD-L1 blockade. Acta Pharm Sin B. (2022) 12:2533–49. doi: 10.1016/j.apsb.2021.11.005
122. Møller SH, Wang L, and Ho PC. Metabolic programming in dendritic cells tailors immune responses and homeostasis. Cell Mol Immunol. (2022) 19:370–83. doi: 10.1038/s41423-021-00753-1
123. Peng X, He Y, Huang J, Tao Y, and Liu S. Metabolism of dendritic cells in tumor microenvironment: for immunotherapy. Front Immunol. (2021) 12:613492. doi: 10.3389/fimmu.2021.613492
124. Wang H, Sun P, Yuan X, Xu Z, Jiang X, Xiao M, et al. Autophagy in tumor immune escape and immunotherapy. Mol Cancer. (2025) 24:85. doi: 10.1186/s12943-025-02277-y
125. Mameli E, Martello A, and Caporali A. Autophagy at the interface of endothelial cell homeostasis and vascular disease. FEBS J. (2022) 289:2976–91. doi: 10.1111/febs.15873
126. Sun Y, Wen F, Yan C, Su L, Luo J, Chi W, et al. Mitophagy protects the retina against anti-vascular endothelial growth factor therapy-driven hypoxia via hypoxia-inducible factor-1α Signaling. Front Cell Dev Biol. (2021) 9:727822. doi: 10.3389/fcell.2021.727822
127. Chen J, Zhang H, Yi X, Dou Q, Yang X, He Y, et al. Cellular senescence of renal tubular epithelial cells in acute kidney injury. Cell Death Discov. (2024) 10:62. doi: 10.1038/s41420-024-01831-9
128. Wang X, Lee J, and Xie C. Autophagy regulation on cancer stem cell maintenance, metastasis, and therapy resistance. Cancers (Basel). (2022) 14:381. doi: 10.3390/cancers14020381
129. Praharaj PP, Patro BS, and Bhutia SK. Dysregulation of mitophagy and mitochondrial homeostasis in cancer stem cells: Novel mechanism for anti-cancer stem cell-targeted cancer therapy. Br J Pharmacol. (2022) 179:5015–35. doi: 10.1111/bph.15401
130. Rainho MA, Siqueira PB, de Amorim ÍSS, Mencalha AL, and Thole AA. Mitochondria in colorectal cancer stem cells - a target in drug resistance. Cancer Drug Resist. (2023) 6:273–83. doi: 10.20517/cdr.2022.116
131. Zhou S, Liu Y, Zhang Q, Xu H, Fang Y, Chen X, et al. Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy. Stem Cell Res Ther. (2023) 14:58. doi: 10.1186/s13287-023-03278-8
132. Chen X, Kadier M, Shi M, Li K, Chen H, Xia Y, et al. Targeting melatonin to mitochondria mitigates castration-resistant prostate cancer by inducing pyroptosis. Small. (2025) 21:e2408996. doi: 10.1002/smll.202408996
133. Bede ÁM, Váróczy C, Polgár Z, Fazekas G, Hegedűs C, Kókai E, et al. The autophagy inhibitor bafilomycin inhibits antibody-dependent natural killer cell-mediated killing of breast carcinoma cells. Int J Mol Sci. (2025) 26:6273. doi: 10.3390/ijms26136273
134. Chen Y, Shu C, Yan Z, Zhang S, Zhang W, Zhao J, et al. Liensinine overcomes EGFR-TKI resistance in lung adenocarcinoma through DRP1-mediated autophagy. Phytomedicine. (2025) 140:156593. doi: 10.1016/j.phymed.2025.156593
135. Zdanowicz A and Grosicka-Maciąg E. The interplay between autophagy and mitochondria in cancer. Int J Mol Sci. (2024) 25:9143. doi: 10.3390/ijms25179143
136. Chen L, Chen D, Pan Y, Mo Y, Lai B, Chen H, et al. Inhibition of mitochondrial OMA1 ameliorates osteosarcoma tumorigenesis. Cell Death Dis. (2024) 15:786. doi: 10.1038/s41419-024-07127-1
137. Ivanova T, Sbirkov Y, Kazakova M, and Sarafian V. Lysosomes and LAMPs as autophagy drivers of drug resistance in colorectal cancer. Cells. (2025) 14:574. doi: 10.3390/cells14080574
138. Yao J, Ma C, Feng K, Tan G, and Wen Q. Focusing on the role of natural products in overcoming cancer drug resistance: an autophagy-based perspective. Biomolecules. (2022) 12:1565. doi: 10.3390/biom12111565
139. Luo L, Lechuga-Vieco AV, Sattentau C, Borsa M, and Simon AK. Dysfunctional mitochondria in ageing T cells: a perspective on mitochondrial quality control mechanisms. EMBO Rep. (2025) 26:4402–18. doi: 10.1038/s44319-025-00536-z
140. Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1/PD-L1 in cancers. Mol Cancer. (2024) 23:108. doi: 10.1186/s12943-024-02023-w
141. Qian C and Cao X. Reversing the mitochondrial stress-induced exhaustion of CD8+ T cells for improving cancer immunotherapy. Cell Mol Immunol. (2021) 18:1634–7. doi: 10.1038/s41423-021-00709-5
142. Zhao Z, Ren Y, Yuan M, Liu G, and Sun J. The molecular mechanisms of mitochondrial dynamics and mitophagy and their complex association with cancer drug resistance. J Transl Med. (2025) 23:1047. doi: 10.1186/s12967-025-07078-x
143. Kovale L, Singh MK, Kim J, and Ha J. Role of autophagy and AMPK in cancer stem cells: therapeutic opportunities and obstacles in cancer. Int J Mol Sci. (2024) 25:8647. doi: 10.3390/ijms25168647
Keywords: drug resistance, gastrointestinal tumors, immune escape, immunotherapy, mitophagy
Citation: Zhang T, Ren Z, Tang B, Man R, Wang L, Wang Q, Peng J and Yu Y (2026) Mitophagy in gastrointestinal tumors: mechanisms and new targets for immunotherapy. Front. Oncol. 15:1717138. doi: 10.3389/fonc.2025.1717138
Received: 02 October 2025; Accepted: 05 December 2025; Revised: 01 December 2025;
Published: 02 January 2026.
Edited by:
Yuchen Lei, Massachusetts General Hospital and Harvard Medical School, United StatesReviewed by:
Xuegang Niu, The First Affiliated Hospital of Fujian Medical University, ChinaTsvetomira Ivanova, Medical University of Plovdiv, Bulgaria
Copyright © 2026 Zhang, Ren, Tang, Man, Wang, Wang, Peng and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Qingyan Wang, d2FuZ3Fpbmd5YW4yMDE5QDE2My5jb20=; Jirun Peng, cGVuZ2pyQG1lZG1haWwuY29tLmNu; Yongduo Yu, eXV5b25nZHVvQDE2My5jb20=
†These authors have contributed equally to this work